Recently, Reig Torras and colleagues have shown that RCC patients harboring Tp53/p53 mutations, together with a mutation in the SMARCA4 gene, exhibit a more aggressive tumor phenotype [43]. This evidence concerns the gene TP53 and renal cell carcinoma.